A novel Buthus martensii Karsch chlorotoxin derivative for glioma SPECT imaging

2020 ◽  
Vol 44 (35) ◽  
pp. 14947-14952
Author(s):  
Lingzhou Zhao ◽  
Jingyi Zhu ◽  
Tiantian Wang ◽  
Changcun Liu ◽  
Ningning Song ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Malignant Glioma ◽  
Therapeutic Potential ◽  
Spect Imaging ◽  
Primary Brain Tumors ◽  
Scorpion Venoms

An increasing number of studies show the diagnostic and therapeutic potential of scorpion venoms and toxins in cancer, including malignant glioma that represents the most fatal primary brain tumors.

scholarly journals P14.37 Depression in patients with primary brain tumors: Relation to clinical variables and tumor characteristics

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii75-iii75
Author(s):  
F John ◽  
G R Barger ◽  
S Mittal ◽  
C Juhasz
Keyword(s):  
Overall Survival ◽  
Brain Tumors ◽  
Depressive Disorder ◽  
Malignant Glioma ◽  
Early Recognition ◽  
Antidepressant Treatment ◽  
Newly Diagnosed ◽  
Recurrent Malignant Glioma ◽  
Primary Brain Tumors ◽  
Increased Risk

Abstract BACKGROUND Patients with brain tumor have an increased risk for depressive disorder, however, the association between depression and clinical or tumor-related variables remains mostly unclear. In this study, we analyzed the relation of depression to several clinical and tumor-related characteristics in patients with primary brain tumors. MATERIAL AND METHODS Sixty patients with newly-diagnosed (n=34) or recurrent (n=26) primary brain tumors (50 gliomas, 10 meningiomas) underwent testing with the Beck Depression Inventory-II (BDI-II). Relation of BDI-II scores to clinical and tumor-related characteristics, including age, Karnofsky Performance Status (KPS) scores, presence of antiepileptic, antidepressant, or steroid treatment, as well as tumor grade, lateralization, and lobar localization, were analyzed. In a subset of recurrent malignant glioma patients, the prognostic value of BDI-II scores on overall survival was also analyzed. RESULTS The mean total BDI-II score was 10±8 (range: 0–37); while 27% of patients (n=16) had BDI-II scores indicating at least mild depressive disorder (≥13), only a portion of them (17%) was on antidepressant treatment. No BDI-II difference was found between gliomas vs. meningiomas or newly-diagnosed vs. recurrent tumors; also, no association was found with any tumor-related characteristics. Antiepileptic or steroid therapy had no association with BDI-II scores, while higher BDI-II scores were observed in patients with ongoing antidepressant therapy (15±10 vs. 8±7, p=0.017). Higher BDI-II total and somatic subscale scores correlated with lower KPS scores (r=-0.32, p=0.014 and r=-0.31, p=0.017, respectively). In recurrent malignant glioma patients (n=18), higher depression scores were associated with shorter survival (hazard ratio: 3.7; 95% confidence interval: 1.0–13.6; p=0.048). CONCLUSION Depression affected more than ¼ of patients with primary brain tumors in this single-center cohort and was independent from most clinical and tumor-related characteristics, except KPS scores. Although most of these patients have mild depression that is often overlooked without targeted screening, higher BDI-II scores may predict shorter overall survival in recurrent malignant glioma patients. These data reinforce the importance of early recognition and treatment of depressive symptoms in patients with primary brain tumors.

Pathologic Analysis of Primary Brain Tumors

1985 ◽  
Vol 3 (4) ◽  
pp. 711-728 ◽  
Author(s):  
Rodney D. McComb ◽  
Peter C. Burger
Keyword(s):  
Brain Tumors ◽  
Primary Brain Tumors ◽  
Pathologic Analysis

Use of Fluorescence to Guide Resection or Biopsy of Primary Brain Tumors and Brain Metastases

2014 ◽  
Vol 75 (S 02) ◽  
Author(s):  
S. Marbacher ◽  
E. Klinger ◽  
L. Schwzer ◽  
I. Fischer ◽  
E. Nevzati ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Brain Metastases ◽  
Primary Brain Tumors

Programmed Cell Death Ligand 1 and Venous Thromboembolism in Patients with Primary Brain Tumors

2019 ◽  
Author(s):  
P. Seyed Mir ◽  
A.-S. Berghoff ◽  
M. Preusser ◽  
G. Ricken ◽  
J. Riedl ◽  
...  
Keyword(s):  
Cell Death ◽  
Venous Thromboembolism ◽  
Programmed Cell Death ◽  
Brain Tumors ◽  
Primary Brain Tumors

scholarly journals Impact of combined use of intraoperative MRI and awake microsurgical resection on patients with gliomas: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Constantin Tuleasca ◽  
Henri-Arthur Leroy ◽  
Iulia Peciu-Florianu ◽  
Ondine Strachowski ◽  
Benoit Derre ◽  
...  
Keyword(s):  
Systematic Review ◽  
Postoperative Complications ◽  
Brain Tumors ◽  
Standard Error ◽  
Complete Resection ◽  
Awake Craniotomy ◽  
Intraoperative Mri ◽  
Primary Brain Tumors ◽  
Combined Use ◽  
Microsurgical Resection

AbstractMicrosurgical resection of primary brain tumors located within or near eloquent areas is challenging. Primary aim is to preserve neurological function, while maximizing the extent of resection (EOR), to optimize long-term neurooncological outcomes and quality of life. Here, we review the combined integration of awake craniotomy and intraoperative MRI (IoMRI) for primary brain tumors, due to their multiple challenges. A systematic review of the literature was performed, in accordance with the Prisma guidelines. Were included 13 series and a total number of 527 patients, who underwent 541 surgeries. We paid particular attention to operative time, rate of intraoperative seizures, rate of initial complete resection at the time of first IoMRI, the final complete gross total resection (GTR, complete radiological resection rates), and the immediate and definitive postoperative neurological complications. The mean duration of surgery was 6.3 h (median 7.05, range 3.8–7.9). The intraoperative seizure rate was 3.7% (range 1.4–6; I^2 = 0%, P heterogeneity = 0.569, standard error = 0.012, p = 0.002). The intraoperative complete resection rate at the time of first IoMRI was 35.2% (range 25.7–44.7; I^2 = 66.73%, P heterogeneity = 0.004, standard error = 0.048, p < 0.001). The rate of patients who underwent supplementary resection after one or several IoMRI was 46% (range 39.8–52.2; I^2 = 8.49%, P heterogeneity = 0.364, standard error = 0.032, p < 0.001). The GTR rate at discharge was 56.3% (range 47.5–65.1; I^2 = 60.19%, P heterogeneity = 0.01, standard error = 0.045, p < 0.001). The rate of immediate postoperative complications was 27.4% (range 15.2–39.6; I^2 = 92.62%, P heterogeneity < 0.001, standard error = 0.062, p < 0.001). The rate of permanent postoperative complications was 4.1% (range 1.3–6.9; I^2 = 38.52%, P heterogeneity = 0.123, standard error = 0.014, p = 0.004). Combined use of awake craniotomy and IoMRI can help in maximizing brain tumor resection in selected patients. The technical obstacles to doing so are not severe and can be managed by experienced neurosurgery and anesthesiology teams. The benefits of bringing these technologies to bear on patients with brain tumors in or near language areas are obvious. The lack of equipoise on this topic by experienced practitioners will make it difficult to do a prospective, randomized, clinical trial. In the opinion of the authors, such a trial would be unnecessary and would deprive some patients of the benefits of the best available methods for their tumor resections.

Sign in / Sign up

Export Citation Format

Share Document